Streptozotocin-induced type 1 diabetes in rodents as a model for studying mitochondrial mechanisms of diabetic β cell glucotoxicity

Jinzi Wu
Liang-Jun Yan
Department of Pharmaceutical Sciences, UNT System College of Pharmacy, University of North Texas Health Science Center, Fort Worth, TX, USA

Abstract: Chronic hyperglycemia and the corresponding glucotoxicity are the main pathogenic mechanisms of diabetes and its complications. Streptozotocin (STZ)-induced diabetic animal models are useful platforms for the understanding of β cell glucotoxicity in diabetes. As diabetes induced by a single STZ injection is often referred to as type 1 diabetes that is caused by STZ's partial destruction of pancreas, one question often being asked is whether the STZ type 1 diabetes animal model is a good model for studying the mitochondrial mechanisms of β cell glucotoxicity. In this mini review, we provide evidence garnered from the literature that the STZ type 1 diabetes is indeed a suitable model for studying mitochondrial mechanisms of diabetic β cell glucotoxicity. Evidence presented includes: 1) continued β cell derangement is due to chronic hyperglycemia after STZ is completely eliminated out of the body; 2) STZ diabetes can be reversed by insulin treatment, which indicates that β cell responds to treatment and shows ability to regenerate; and 3) STZ diabetes can be ameliorated or alleviated by administration of phytochemicals. In addition, mechanisms of STZ action and fundamental gaps in understanding mitochondrial mechanisms of β cell dysfunction are also discussed.

Keywords: diabetes, β cell, glucotoxicity, mitochondria, redox imbalance, streptozotocin

Introduction
Diabetes mellitus and its complications are chronic glucotoxicity diseases. The concept of β cell glucotoxicity (and other cells as well) implicates that persistent excessive glucose can exert adverse or toxic effect on β cell function after the establishment of diabetes induced by either genetic or environmental factors.1 Hence, diabetic glucotoxicity is believed to play a forceful role in driving secondary β cell failure in both type 1 and type 2 diabetes.2,3 Despite intensive and extensive studies on β cell glucotoxicity, detailed mitochondrial mechanisms still remain poorly understood. In this regard, experimental animal models of diabetes have been indispensable to research in diabetes and its complications.

Streptozotocin-induced animal models of diabetes
Streptozotocin (STZ) is a widely used chemical for the induction of experimental diabetes in rodents.4,5 Since the initial report of its diabetogenic properties in 1963,6 STZ has been used alone or in combination with other chemicals or with dietary manipulations for induction of either type 1 or type 2 diabetes.7,8 Type 1 diabetes can be induced in rodents by a single STZ injection9,10 while type 2 diabetes can be induced by at least three approaches, which include STZ injection after administration of nicotinamide,11,12 high fat diet (HFD) feeding followed by a low-dose STZ injection,13...
and STZ injection during the neonatal period.\textsuperscript{14,15} All these STZ-involved diabetic animal models have been very useful in elucidating the mechanisms of diabetic pathogenesis and in screening artificial chemicals, natural products, and pharmacological agents that are potentially capable of lowering blood glucose levels.\textsuperscript{16,17}

**Mechanisms of STZ action**

STZ is an antibiotic produced by the bacterium *Streptomyces achromogens* and possesses a broad spectrum of antibacterial properties.\textsuperscript{18} It contains a glucose molecule (in deoxy form) that is linked to a highly reactive methylnitrosourea moiety (Figure 1) that is thought to exert STZ's cytotoxic effects, while the glucose moiety directs the chemical to the pancreatic \( \beta \) cells.\textsuperscript{19} STZ recognizes the GLUT2 receptor that is abundant on \( \beta \) cell plasma membranes.\textsuperscript{5} Therefore, pancreatic \( \beta \) cell is a specific target of STZ. As GLUT2 also exists in liver and kidney to a less extent,\textsuperscript{20} high doses of STZ could also impair the functions of liver and kidney.\textsuperscript{20} Upon ingestion, STZ is rapidly metabolized in the liver and quickly eliminated by renal excretion;\textsuperscript{21} therefore, STZ has really a short life (with a half-life of 15 minutes in the serum after IV injection\textsuperscript{22}) and its acute toxicity to the liver and the kidney can be neglected after persistent hyperglycemia is obtained.\textsuperscript{23} After STZ is eliminated out of the body, any further functional impairment of the liver and the kidney may be attributed to the effects of diabetic hyperglycemia. This is the basis for studying the mechanisms of STZ diabetic complications in these organs\textsuperscript{23} as well as other organs such as the brain, the heart, and the muscles.\textsuperscript{24}

![Figure 1 Chemical structure of streptozotocin.](image)

**Potential mechanisms of diabetic \( \beta \) cell glucotoxicity**

When there is a status of persistent hyperglycemia as opposed to episodic hyperglycemia, cellular metabolic system is under constant pressure due to glucose overloading.\textsuperscript{25} This glucose overloading can activate many metabolic or signaling pathways that not only attempt to dispose excessive glucose but also generate more reactive oxygen species, leading to oxidative stress and \( \beta \) cell failure.\textsuperscript{1} As shown in Figure 2, these hyperglycemia-stimulated pathways include an increased NADH/NAD\(^+\) ratio linked to pseudohypoxia and reductive stress,\textsuperscript{25} the hexosamine pathway responsible for protein O-GlcNAc modifications;\textsuperscript{26} protein kinase C activation,\textsuperscript{27} activation of the polyol pathway resulting in accumulation of sorbitol and fructose,\textsuperscript{28} formation of methylglyoxal and advanced glycation products,\textsuperscript{29} enediol formation,\textsuperscript{30} and endoplasmic reticulum stress.\textsuperscript{31} The establishment that all these pathways culminate in reactive oxygen species production,\textsuperscript{32} together with the evidence of a low-level antioxidant capacity in \( \beta \) cells,\textsuperscript{1} is thought to be responsible for secondary diabetic \( \beta \) cell failure.\textsuperscript{3} Nonetheless, the mitochondrial mechanisms of \( \beta \) cell glucotoxicity in diabetes still remain poorly understood.

**Glucose combustion, mitochondrial ATP production, and \( \beta \) cell insulin secretion**

It is well established that glucose-stimulated insulin secretion is tightly linked to glucose-driven ATP production by \( \beta \) cell mitochondria.\textsuperscript{33,34} As \( \beta \) cell has a very low level of lactate dehydrogenase,\textsuperscript{35} most of the pyruvate generated by the glycolytic pathway is transported into mitochondria to generate the reducing compounds NADH and FADH\(_2\), along with a complete combustion of pyruvate to CO\(_2\).\textsuperscript{36} This process is achieved not only by formation of acetyl-CoA that feeds into the Krebs cycle but also by formation of oxaloacetate that replenishes the intermediates in the Krebs cycle.\textsuperscript{37} When blood glucose gets higher after a meal, ATP production in \( \beta \) cell mitochondria also gets higher (Figure 3). This leads to an elevated level of ATP/ADP ratio in the cytoplasm and a consequent closure of the kATP channels on the cell membrane. The closure of the kATP channels then depolarizes the membranes and renders the opening of the calcium channel, resulting in calcium influx that triggers insulin granule exocytosis and insulin release\textsuperscript{38–40} (Figure 3). In diabetes, however, this episodic process of glucose-stimulated insulin secretion is believed to be impaired.\textsuperscript{41,42}

**Redox imbalance and mitochondrial deregulation in \( \beta \) cell dysfunction**

Although pancreatic \( \beta \) cell function operates by a supply driven mechanism by which glucose or nutrient metabolism is coupled to insulin secretion,\textsuperscript{37} persistent stimulation of \( \beta \) cell
Mechanisms of diabetic β cell glucotoxicity

Figure 2 Mechanisms by which diabetic hyperglycemia can impose glucotoxicity on β cells.
Notes: The biochemical pathways listed can be upregulated or activated by chronic hyperglycemia. Importantly, all these pathways are eventually involved in elevated production of reactive oxygen species that are detrimental to β cell function. These pathways can be dissected by animal models of STZ diabetes.
Abbreviations: STZ, streptozotocin; ROS, reactive oxygen species.

Figure 3 Glucose combustion is tightly coupled to insulin secretion in pancreatic β cells.
Notes: The figure shown depicts the main pathways of glucose metabolism and mitochondrial ATP production. Glucose is first transported into β cells via GLUT2 transporters, followed by glycolysis, Krebs cycle, and oxidative phosphorylation that eventually make ATP from the combustion of glucose. The elevated ratio of ATP/ADP, driven by high blood glucose, closes the KATP channel and opens the calcium channel on the cell membranes. The influx of calcium triggers exocytosis of insulin granules and subsequent insulin release.
Abbreviation: TCA, tricarboxylic acid.
by a high level of glucose could eventually lead to β cell exhaustion and cell death. This glucotoxicity has been thought to originate from redox imbalance between NADH and NAD⁻. On one hand, NADH can be overproduced by hyperglycemia and the activation of polyol pathway that makes NADH from NADPH; on the other hand, NAD⁻ can be depleted by the activation of enzymes such as poly ADP-ribosylase, sirtuins, and CD38 that use NAD⁺ as their substrate. Therefore, exceedingly accumulation of NADH and potential depletion of NAD⁺ indicate a severe problem in NADH/NAD⁺ recycling under diabetic conditions. As mitochondria is the major cellular site for maintaining redox balance by oxidizing NADH via complex I and FADH₂ via complex II, mitochondrial electron transport chain plays a critical role in β cell function and dysfunction. Nonetheless, the role of each component of the electron transport chain, in particular, that of complex I (Figure 4), in diabetic β cell glucotoxicity remains largely unknown. Additionally, the roles of those mitochondrial dehydrogenases in making NADH from NAD⁺ (Figure 4) are also unknown. From this perspective, STZ diabetic animal models should provide a broad platform for exploring the mitochondrial mechanism of diabetic glucotoxicity, implicating each component of the electron transport chain.

### STZ-induced type 1 diabetes as an animal model for further exploring the mitochondrial mechanisms of diabetic β cell glucotoxicity

Our laboratory recently embarked on studies of mitochondrial mechanisms of β cell glucotoxicity using animal models of diabetes induced by a single intraperitoneal STZ injection. While there is no doubt that STZ-induced type 2 diabetes are good models for studying mitochondrial glucotoxicity in β cells, one question often being asked is that whether the STZ type 1 diabetes model is suitable for studying β cell diabetic glucotoxicity as STZ partially destructs pancreas and reduces β cell mass. After reviewing the literature, we firmly believe that the single STZ injection diabetic animal model is appropriate for studying the mitochondrial mechanisms of β cell glucotoxicity. Specifically, our belief is based on the following experimental evidence reported in the literature.

1. STZ is rapidly eliminated after ingestion. For intraperitoneal injection, STZ can be eliminated within 48 hours of ingestion and its DNA methylating effect quickly diminishes as no further increase in DNA methylation can be detected after 24 hours of STZ exposure. These pieces of evidence indicate that STZ acute toxicity

---

**Figure 4**: Role of redox imbalance between NADH and NAD⁺ in β cell dysfunction.

**Notes**: Under euglycemic condition, the balance between NADH and NAD⁺ is well maintained. However, under diabetic hyperglycemic condition, the balance between NADH and NAD⁺ is broken by several mechanisms such as NADH overproduction via the glycolytic and the polyol pathways and NAD⁺ depletion by poly ADP-ribosylase, sirtuins, and CD38. In spite of intensive studies in the field of diabetes, the role of complex I that makes NAD⁺ from NADH in this redox imbalance is unknown, so is the role of those enzymes making NADH from NAD⁺.

---

**STZ-induced type 1 diabetes as an animal model for further exploring the mitochondrial mechanisms of diabetic β cell glucotoxicity**

Our laboratory recently embarked on studies of mitochondrial mechanisms of β cell glucotoxicity using animal models of diabetes induced by a single intraperitoneal STZ injection. While there is no doubt that STZ-induced type 2 diabetes are good models for studying mitochondrial glucotoxicity in β cells, one question often being asked is that whether the STZ type 1 diabetes model is suitable for studying β cell diabetic glucotoxicity as STZ partially destructs pancreas and reduces β cell mass. After reviewing the literature, we firmly believe that the single STZ injection diabetic animal model is appropriate for studying the mitochondrial mechanisms of β cell glucotoxicity. Specifically, our belief is based on the following experimental evidence reported in the literature.

1. **STZ is rapidly eliminated after ingestion.** For intraperitoneal injection, STZ can be eliminated within 48 hours of ingestion and its DNA methylating effect quickly diminishes as no further increase in DNA methylation can be detected after 24 hours of STZ exposure. These pieces of evidence indicate that STZ acute toxicity
is very short-lived after ingestion. Yet, β cell function continues to deteriorate in the absence of detectable STZ.\textsuperscript{99} It is now known that it is the hyperglycemic state established by acute STZ toxicity that drives further β cell derangement.\textsuperscript{51,52} Therefore, after induction of diabetes, β cell dysfunction is maintained by persistent hyperglycemia, and such β cell can be explored to provide insights into the mitochondrial mechanisms of glucotoxicity.

2) **STZ diabetes can be reversed by insulin treatment.** Grossman et al have reported that glycemic control in STZ diabetic mice by insulin can promote β cell regeneration in the diabetic pancreas,\textsuperscript{53} demonstrating again that further β cell dysfunction, in the absence of STZ, is due to diabetic hyperglycemia. Once this hyperglycemic status is reversed to euglycemia by insulin supplement, β cell function improves via β cell regeneration.\textsuperscript{55} In fact, while animals show insulin deficiency after STZ ingestion, they do not require insulin treatment for survival.\textsuperscript{54} Therefore, many diabetic animals can live beyond 24 weeks without any interventions after a single STZ injection,\textsuperscript{54} indicating that the dosage of STZ given as a single injection only partially destructs islets and β cells\textsuperscript{54,55} and that diabetes created as such is due to β cell glucotoxicity rather than STZ acute toxicity. The results of Grossman’s study agree well with those of other studies that β cell function indeed responds to treatment and may have limited regeneration after partial pancreatic destruction by STZ.\textsuperscript{52,56,57} On the other hand, the use of high STZ doses (eg, 100 mg/kg for rats) could lead to nearly a complete destruction of β cells, which is often associated with a quick demise of the animals.\textsuperscript{54} However, the use of a very high STZ dose is never the case for studies of drug-screening and of glucotoxicity in diabetes and diabetic complications.

3) **β cell dysfunction in STZ diabetes can be alleviated by plant natural products or phytochemicals.** In fact, this is the basis for screening diabetic drugs or compounds using STZ diabetic animal models. In addition to DNA alkylation thought to be involved in STZ β cell toxicity,\textsuperscript{4,5} oxidative damage by reactive oxygen or reactive nitrogen species has also been implicated in β cell destruction by STZ.\textsuperscript{4,5} Therefore, numerous studies have demonstrated that plant extracts or phytochemicals having antioxidant properties can ameliorate β cell dysfunction in STZ diabetes. For example, grape seed proanthocyanidins,\textsuperscript{58} curcumin,\textsuperscript{59} resveratrol,\textsuperscript{60} and pycnogenol\textsuperscript{61} all have been reported to improve β cell function in STZ diabetic animals. The underlying mechanisms of these phytochemicals are likely due to their abilities to attenuate hyperglycemic glucotoxicity by decreasing blood glucose levels and/or facilitating glucose combustion, leading to an eventual rebalanced redox state between NADH and NAD\textsuperscript{+}\textsuperscript{,62-64} which is conducive to proliferation of surviving β cell or regeneration of β cell from other type of cells such as acinar and ductal cells.\textsuperscript{10,20,56} It is unlikely that hyperglycemia-impaired β cell would be a direct target for repairing by these phytochemicals or other glucose lowering agents.

**Summary and conclusion**

In summary, as the initial STZ toxicity to β cells is short-lived\textsuperscript{11} and further impairment of the surviving β cell’s function is due to hyperglycemic toxicity,\textsuperscript{24,51,65} the mitochondrial mechanisms of β cell glucotoxicity in these surviving β cells can thus be elucidated (Figure 5). Additionally, as STZ-destructed cells undergo necrosis and are eliminated by macrophages,\textsuperscript{66,67} no intact mitochondria may be isolated from these STZ-destructed cells; thus, mitochondria isolated from STZ-exposed pancreas should be from those surviving or hyperglycemia-impaired β cells (Figure 5). Based on these findings, we believe that animal models of diabetes induced by single STZ injection can serve as a platform for studying the mitochondrial mechanisms of β cell glucotoxicity. Of course, no mitochondria isolation and functional analysis should be performed right after STZ injection in order to avoid any acute toxic effects of STZ on mitochondria. Rather, mitochondria should be isolated when overt diabetes develops after STZ is completely eliminated out of the body. The point here is that it should be distinguished between STZ acute toxicity and diabetic glucotoxicity when needed for given STZ diabetes settings.

In conclusion, STZ-induced type 1 diabetes in rodents is a well-established and well-accepted practice for the studies of pathogenesis of diabetes and its complications. However, it should be pointed out that this STZ model has both advantages and disadvantages over other STZ-involved experimental models, including STZ-neonatal and STZ-HFD. On one hand, when compared with the STZ-neonatal and STZ-HFD models that can also be used to study the mitochondrial mechanisms of β cell glucotoxicity, the single STZ injection model is much less expensive and much less time-consuming. For example, in the STZ-HFD model, HFD feeding usually takes a few weeks or a few months followed by low-dose STZ injections.\textsuperscript{13,16,68} Similarly, the STZ-neonatal model also takes a longer time for diabetes to develop in addition to caring and manipulating neonatal animals.\textsuperscript{15,69} On the other hand, the disadvantage of the single STZ injection model is that it
does not create the insulin resistance pathophysiology that can be observed in the STZ-neonatal and STZ-HFD models. Additionally, no standard protocols exist for STZ preparation and injections, and the diabetic state can be highly variable due to factors such as age of animals, sex, body weight, species, and strains. Moreover, it is by no means that the STZ type 1 diabetic animal model would be equivalent to the human disease state. Nonetheless, the single STZ injection model should continue to provide a cost-effective, time-saving, convenient platform for the study of the pathophysiological mitochondrial mechanisms of β cell derangement induced by diabetic glucotoxicity.

**Acknowledgment**

This publication was supported in part by National Institute of Neurological Disorders and Stroke, Grant R01NS079792.

**Disclosure**

The authors declare that there is no conflict of interest.

**References**


